{
    "startDate": "2019-08-01",
    "endDate": "2020-04-30",
    "year": "2020",
    "quarter": "Q3",
    "symbol": "RFL",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents at beginning of period",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 8430000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 336000
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 9162000
            },
            {
                "label": "Total",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 47811000
            },
            {
                "label": "Investments \u2013 Rafael Pharmaceuticals",
                "concept": "LongTermInvestments",
                "unit": "usd",
                "value": 70018000
            },
            {
                "label": "Deferred income tax assets, net",
                "concept": "DeferredTaxAssetsNetNoncurrent",
                "unit": "usd",
                "value": 6000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsCurrent",
                "unit": "usd",
                "value": 1484000
            },
            {
                "label": "Total current assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 137431000
            },
            {
                "label": "Trade accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 700000
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 728000
            },
            {
                "label": "Other current liabilities",
                "concept": "OtherLiabilitiesCurrent",
                "unit": "usd",
                "value": 57000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 1485000
            },
            {
                "label": "Due to Related Party",
                "concept": "DueToRelatedPartiesNoncurrent",
                "unit": "usd",
                "value": 27000
            },
            {
                "label": "Convertible note, net of discount of $0 and $54 \u2013 Related Party",
                "concept": "ConvertibleDebtNoncurrent",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Other liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 92000
            },
            {
                "label": "Accrued interest on convertible note \u2013 Related Party",
                "concept": "LongTermNotesPayable",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total current liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 1604000
            },
            {
                "label": "Commitments and Contingencies Disclosure [Abstract]",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 128998000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -10850000
            },
            {
                "label": "Accumulated other comprehensive income related to foreign currency translation adjustment",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": 3752000
            },
            {
                "label": "Total equity attributable to Rafael Holdings, Inc.",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 122057000
            },
            {
                "label": "Noncontrolling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": 13770000
            },
            {
                "label": "TOTAL EQUITY",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 135827000
            },
            {
                "label": "TOTAL LIABILITIES AND EQUITY",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 137431000
            }
        ],
        "cf": [
            {
                "label": "Consolidated Net Loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -5223000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 1413000
            },
            {
                "label": "Deferred income taxes",
                "concept": "DeferredIncomeTaxesAndTaxCredits",
                "unit": "usd",
                "value": 13000
            },
            {
                "label": "Gain on sales of marketable securities, net",
                "concept": "MarketableSecuritiesGainLoss",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Impairment of investments \u2013 Other Pharmaceuticals",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": 295000
            },
            {
                "label": "Equity in earnings of RP Finance",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": 53000
            },
            {
                "label": "Provision for doubtful accounts",
                "concept": "ProvisionForDoubtfulAccounts",
                "unit": "usd",
                "value": 48000
            },
            {
                "label": "Non-cash compensation",
                "concept": "EmployeeBenefitsAndShareBasedCompensationNoncash",
                "unit": "usd",
                "value": 546000
            },
            {
                "label": "Amortization of debt discount",
                "concept": "AmortizationOfDebtDiscountPremium",
                "unit": "usd",
                "value": 54000
            },
            {
                "label": "Trade accounts receivable",
                "concept": "IncreaseDecreaseInAccountsReceivable",
                "unit": "usd",
                "value": 141000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 171000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": -72000
            },
            {
                "label": "Accounts payable and accrued expenses",
                "concept": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "unit": "usd",
                "value": 28000
            },
            {
                "label": "Due to/from related parties",
                "concept": "IncreaseDecreaseInDueFromRelatedParties",
                "unit": "usd",
                "value": 107000
            },
            {
                "label": "Accrued interest \u2013 Related Party",
                "concept": "InterestExpenseRelatedParty",
                "unit": "usd",
                "value": 19000
            },
            {
                "label": "Other current liabilities",
                "concept": "IncreaseDecreaseInOtherCurrentLiabilities",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -2975000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 491000
            },
            {
                "label": "Proceeds from sale and maturity of marketable securities, net",
                "concept": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Investment in Rafael Pharmaceuticals",
                "concept": "PaymentsToAcquireInvestments",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Net cash used in investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -491000
            },
            {
                "label": "Contribution from noncontrolling interest of consolidated entity",
                "concept": "ProceedsFromMinorityShareholders",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Repayment of Loan from Rafael Pharmaceuticals",
                "concept": "ProceedsFromRepaymentsOfDebt",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Proceeds from exercise of options",
                "concept": "ProceedsFromStockOptionsExercised",
                "unit": "usd",
                "value": 29000
            },
            {
                "label": "Proceed from sale of shares",
                "concept": "ProceedsFromIssuanceOrSaleOfEquity",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Proceeds from convertible notes payable - Related Party",
                "concept": "ProceedsFromConvertibleDebt",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Net cash (used in) provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": -96000
            },
            {
                "label": "Effect of exchange rate changes on cash and cash equivalents",
                "concept": "EffectOfExchangeRateOnCashAndCashEquivalents",
                "unit": "usd",
                "value": -32000
            },
            {
                "label": "Net decrease in cash and cash equivalents",
                "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease",
                "unit": "usd",
                "value": -3594000
            }
        ],
        "ic": [
            {
                "label": "Rental \u2013 Third Party",
                "concept": "OperatingLeasesIncomeStatementLeaseRevenue",
                "unit": "usd",
                "value": 1076000
            },
            {
                "label": "Rental \u2013 Related Party",
                "concept": "RevenueFromRelatedParties",
                "unit": "usd",
                "value": 1570000
            },
            {
                "label": "Total Revenue",
                "concept": "Revenues",
                "unit": "usd",
                "value": 3670000
            },
            {
                "label": "Selling, general and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 6343000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 1327000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 1413000
            },
            {
                "label": "Interest (expense) income, net",
                "concept": "InterestIncomeExpenseNet",
                "unit": "usd",
                "value": -31000
            },
            {
                "label": "Net gain (loss) resulting from foreign exchange transactions",
                "concept": "ForeignCurrencyTransactionGainLossBeforeTax",
                "unit": "usd",
                "value": -5000
            },
            {
                "label": "Gain on sales of marketable securities, net",
                "concept": "MarketableSecuritiesGainLoss",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Impairment of investments \u2013 Other Pharmaceuticals",
                "concept": "ImpairmentOfInvestments",
                "unit": "usd",
                "value": 295000
            },
            {
                "label": "(Provision for) benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": 24000
            },
            {
                "label": "Equity in earnings of RP Finance",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": 53000
            },
            {
                "label": "Net (loss) attributable to noncontrolling interests",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -213000
            },
            {
                "label": "Net Loss Attributable to Rafael Holdings, Inc.",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -5010000
            },
            {
                "label": "Foreign currency translation adjustments",
                "concept": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
                "unit": "usd",
                "value": -32000
            },
            {
                "label": "Total Comprehensive Loss",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -5255000
            },
            {
                "label": "Total Comprehensive Loss attributable to Rafael Holdings, Inc.",
                "concept": "OtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -5236000
            },
            {
                "label": "Loss Per Share:",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -0.32
            },
            {
                "label": "Basic and diluted (in Shares)",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 15747709
            }
        ]
    }
}